{"disease":{"id":"chronic-hepatitis-c-genotype-1","name":"chronic hepatitis c genotype 1"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (genotype 1)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odv-25-mg","indication_name":"Chronic Hepatitis C (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODV 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":0,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02581163","title":"Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT01425203","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":238,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02669940","title":"Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03485846","title":"Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"R-Pharm","has_results":false},{"nct_id":"NCT04246723","title":"Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"R-Pharm","has_results":false},{"nct_id":"NCT01194037","title":"A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"HanAll BioPharma Co., Ltd.","has_results":false},{"nct_id":"NCT00882193","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of Nebraska","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}